Source: CureToday articles
Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be presented at ASCO 2025.
Recent Content
- FDA OKs Investigational New Drug Application for VS-7375 in Solid Tumors
- Hydroxyurea Produces Long-Term Clinical Benefits in Pediatrics With Sickle Cell Anemia
- Crafting an Individual Treatment Plan for Patients With Prostate Cancer
- DPYD Testing Gains Ground: NCCN Guideline Update Reflects Decades of Work Toward Safer Chemotherapy
- NCCN Flash Update: Changes to Colon Cancer Guidelines, Version 3.2025
- Commitment to Patients Is Driven by a Lasting Promise
- AAN 2025: Low-Sodium Oxybate Improves Sleep Quality, Daily Functioning in Narcolepsy, Idiopathic Hypersomnia
- Understanding the FDA Imfinzi Combo Approval for Bladder Cancer Care
- New Options for ER+ Breast Cancer Spotlighted at Patient Event
- Asembia’s AXS25 Summit: Must-See Sessions, Expert Interviews as Specialty Pharmacy Gathers